[go: up one dir, main page]

BRPI0908229A2 - método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero. - Google Patents

método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero.

Info

Publication number
BRPI0908229A2
BRPI0908229A2 BRPI0908229A BRPI0908229A BRPI0908229A2 BR PI0908229 A2 BRPI0908229 A2 BR PI0908229A2 BR PI0908229 A BRPI0908229 A BR PI0908229A BR PI0908229 A BRPI0908229 A BR PI0908229A BR PI0908229 A2 BRPI0908229 A2 BR PI0908229A2
Authority
BR
Brazil
Prior art keywords
corticosteroid
dexamethasone
dispensing
iontophoretically
eye
Prior art date
Application number
BRPI0908229A
Other languages
English (en)
Inventor
Cook Gary
Jaffe Mike
Patane Mike
Calias Perry
Original Assignee
Eyegate Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyegate Pharma S A S filed Critical Eyegate Pharma S A S
Publication of BRPI0908229A2 publication Critical patent/BRPI0908229A2/pt
Publication of BRPI0908229A8 publication Critical patent/BRPI0908229A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Steroid Compounds (AREA)
BRPI0908229A 2008-02-25 2009-02-24 Uso de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste, kit e dispositivo para dispensar iontoforeticamente um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente para tratar um distúrbio ocular mediado por inflamação no referido paciente, e, formulação apropriada para dispensação iontoforética ocular de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente BRPI0908229A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3126708P 2008-02-25 2008-02-25
US4795008P 2008-04-25 2008-04-25
PCT/US2009/034977 WO2009108626A2 (en) 2008-02-25 2009-02-24 Enhanced delivery of a therapeutic to ocular tissues through iontophoresis

Publications (2)

Publication Number Publication Date
BRPI0908229A2 true BRPI0908229A2 (pt) 2017-06-13
BRPI0908229A8 BRPI0908229A8 (pt) 2017-10-10

Family

ID=41016683

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908229A BRPI0908229A8 (pt) 2008-02-25 2009-02-24 Uso de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste, kit e dispositivo para dispensar iontoforeticamente um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente para tratar um distúrbio ocular mediado por inflamação no referido paciente, e, formulação apropriada para dispensação iontoforética ocular de um corticosteróide, derivado de corticosteróide, pró-fármaco ou sal deste no olho de um paciente

Country Status (10)

Country Link
US (4) US20090306579A1 (pt)
EP (1) EP2249921B1 (pt)
JP (1) JP2011512903A (pt)
CN (1) CN101970042A (pt)
AU (1) AU2009219426B2 (pt)
BR (1) BRPI0908229A8 (pt)
CA (1) CA2716390C (pt)
IL (1) IL207014A0 (pt)
MX (1) MX2010009157A (pt)
WO (1) WO2009108626A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970042A (zh) 2008-02-25 2011-02-09 眼门药品公司 经由离子电渗法增强递送治疗药物至眼部组织
WO2010078246A1 (en) * 2008-12-31 2010-07-08 Eyegate Pharma S.A.S. System and method for ocular iontophoresis with buffering
WO2012095877A1 (en) * 2011-01-12 2012-07-19 Sooft Italia Spa Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
WO2012162459A1 (en) * 2011-05-26 2012-11-29 Pepose Jay Device and method for administering eye medications
JP5463511B1 (ja) * 2013-05-13 2014-04-09 株式会社メディカル・アート イオン泳動式皮膚感染症治療装置
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015164626A2 (en) * 2014-04-23 2015-10-29 Seros Medical, Llc Vacuum-assisted drug delivery device and method
KR20170046146A (ko) * 2014-08-13 2017-04-28 더 존스 홉킨스 유니버시티 각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자
ES2874562T3 (es) * 2014-12-19 2021-11-05 Kemin Ind Inc Suministro intraocular de moléculas bioactivas mediante el uso de iontoforesis
EP3247452A4 (en) 2015-01-22 2018-11-14 Eyegate Pharmaceuticals, Inc. Iontophoretic contact lens
MY186271A (en) 2015-03-05 2021-07-01 Auckland Uniservices Ltd Ophthalmic compositions and methods of use therefor
WO2019089537A1 (en) 2017-10-31 2019-05-09 Tusker Medical, Inc. Systems, apparatus, and methods for delivery of therapeutic substance to nasal cavity
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4279900A (en) * 1978-07-13 1981-07-21 Intrex Research Corporation Prodrugs for the improved delivery of halogen-containing glucocorticosteroids
US4456602A (en) * 1982-08-23 1984-06-26 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4443440A (en) * 1982-08-30 1984-04-17 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4472392A (en) * 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4469689A (en) * 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US4588718A (en) * 1984-03-28 1986-05-13 The Upjohn Company Carboxy containing ester prodrugs of corticosteroids
GB9024005D0 (en) * 1990-11-05 1990-12-19 British Bio Technology Process for amplifying nucleic acid
US5222936A (en) * 1991-09-25 1993-06-29 Stephen Robert L Intracorporeal iontophoretic method
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
CA2172983A1 (en) * 1993-09-29 1995-04-06 Kei Sugai 21-substituted steroid compound
US6650934B2 (en) * 1996-12-17 2003-11-18 Alza Corp Polymeric foam reservoirs for an electrotransport delivery device
US6050934A (en) * 1997-02-26 2000-04-18 Cv Dynamics, Inc. Urinary catheter having palpitatable discharge valve with protective shoulders
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
CN1063944C (zh) * 1997-04-14 2001-04-04 齐鲁制药厂 眼用复方妥布霉素混悬液的制法
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
JP2000316991A (ja) 1999-05-13 2000-11-21 Hisamitsu Pharmaceut Co Inc イオントフォレーシス装置の電極構造体及びその製造方法
JP4414517B2 (ja) * 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
CN1158994C (zh) * 1999-09-24 2004-07-28 爱尔康公司 含环丙沙星和地塞米松的局部悬浮制剂
US6395756B2 (en) * 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
US6697668B2 (en) 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
JP2006518769A (ja) * 2003-02-21 2006-08-17 サン・ファーマシューティカル・インダストリーズ・リミテッド 安定な眼科用組成物
JP3493359B1 (ja) * 2003-03-20 2004-02-03 宣美 辛島 イオン泳動式治療装置
FR2855761B1 (fr) * 2003-06-03 2006-02-24 Optis France Sa Dispositif oculaire de delivrance variable de principes actifs par iontophorese
JP4820647B2 (ja) * 2003-08-29 2011-11-24 久光製薬株式会社 イオントフォレーシス投与組成物
JP2008500282A (ja) * 2004-04-08 2008-01-10 レットメッド ピーティーワイ リミテッド 眼症状の治療
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
WO2006014484A2 (en) 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
WO2006072887A1 (en) 2005-01-05 2006-07-13 Eyegate Pharma Sa Ocular iontophoresis device for delivering sirna and aptamers
US8386030B2 (en) * 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8099162B2 (en) * 2005-11-29 2012-01-17 Eyegate Pharma, S.A.S. Ocular iontophoresis device
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US20080027371A1 (en) * 2006-07-26 2008-01-31 Higuchi John W Method and device for minimally invasive site specific ocular drug delivery
WO2008057360A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
CN101970042A (zh) 2008-02-25 2011-02-09 眼门药品公司 经由离子电渗法增强递送治疗药物至眼部组织
CA2723458C (en) * 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
AU2009219426B2 (en) 2015-12-03
AU2009219426A1 (en) 2009-09-03
BRPI0908229A8 (pt) 2017-10-10
US20090306579A1 (en) 2009-12-10
MX2010009157A (es) 2010-09-24
US20140046242A1 (en) 2014-02-13
US10376463B2 (en) 2019-08-13
WO2009108626A2 (en) 2009-09-03
JP2011512903A (ja) 2011-04-28
EP2249921B1 (en) 2020-06-17
US9820935B2 (en) 2017-11-21
CN101970042A (zh) 2011-02-09
US20120283231A1 (en) 2012-11-08
IL207014A0 (en) 2010-12-30
CA2716390C (en) 2016-08-23
US20160263024A1 (en) 2016-09-15
EP2249921A4 (en) 2015-02-11
US9149525B2 (en) 2015-10-06
EP2249921A2 (en) 2010-11-17
CA2716390A1 (en) 2009-09-03
WO2009108626A3 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
BRPI0908229A2 (pt) método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero.
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BRPI0810118A2 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
BR112012021522A2 (pt) bráquete ortodôntico para um sistema ortodôntico, sistema de bráquete ortodôntico, kit ortodôntico, processo para fabricar um bráquete ortodôntico e método para tratar a mordida de um paciente humano
FR2933582B1 (fr) Dispositif de traitement des matieres keratiniques humaines
WO2010068281A3 (en) Contact lens drug delivery device
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
IL225930B (en) Apparatus and method for detecting amyloid in a retina in a diagnosis, advancement, and prognosing of alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of neurodegenerative dissorders, and ocular diseases
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
EP2451384A4 (en) IMPLANTABLE LUBRICATING DEVICE AND METHOD FOR THE TREATMENT OF ANIMAL MUG OR A HUMAN PATIENT USING THIS DEVICE
BRPI0915893A8 (pt) métodos e aparelho para introdução de um dispositivo médico dentro do corpo de um paciente
WO2010083338A3 (en) Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
WO2014178931A8 (en) Sobetirome in the treatment of myelination diseases
FR2932979B1 (fr) Dispositif introducteur s'etendant entre un point proximal et un point distal et necessaire de traitement associe.
BR112012002001A2 (pt) método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
EP2816984A4 (en) DEVICE AND METHOD FOR THE TREATMENT OF NETWORK DISPOSAL AND OTHER EYES
BRPI1008727A2 (pt) derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BRPI0718041A2 (pt) Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2852422A4 (en) ROUNDED DEVICE FOR PREVENTING POSTERIOR CAPTURE ILLUMINATION

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EYEGATE PHARMACEUTICALS, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61N 1/30

Ipc: A61N 1/04 (1968.09), A61K 9/00 (1968.09), A61K 31/

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61N 1/04 , A61K 9/00 , A61K 31/573 , A61N 1/30 , A61K 41/00 , A61F 9/00

Ipc: A61K 31/573 (2006.01), A61K 9/00 (2006.01), A61N 1

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL